Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents

References

• Hotez PJ, Bottazzi ME, Franco-Paredes C, et al. The neglected tropical diseases of latin America and the caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008;2:e300.
   PubMed Web of Science ®Google Scholar
• Coura JR, Junqueira AC, Fernandes O, et al. Emerging chagas disease in amazonian Brazil. Trends Parasitol. 2002;18:171–176.
   PubMed Web of Science ®Google Scholar
• WHO. Chagas disease (American trypanosomiasis). 2017.
   Google Scholar
• Vougogiannopoulou K, Skaltsounis AL. From tyrian purple to kinase modulators: naturally halogenated indirubins and synthetic analogues. Planta medica. 2012;78:1515–1528.
   PubMed Web of Science ®Google Scholar
• Kalsi DS, Ward J, Lee R, et al. Purple urine bag syndrome: a rare spot diagnosis. Dis Markers. 2017;2017:9131872.
   PubMed Web of Science ®Google Scholar
• Gaboriaud-Kolar N, Vougogiannopoulou K, Skaltsounis AL. Indirubin derivatives: a patent review (2010 - present). Expert Opin Ther Pat. 2015;25:583–593.
   PubMed Web of Science ®Google Scholar
• Zhou A, Yan L, Lai F, et al. Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds. Bioorg Med Chem Lett. 2017;27:3326–3331.
   PubMed Web of Science ®Google Scholar
• Cheng X, Merz KH, Vatter S, et al. Identification of a water-soluble indirubin derivative as potent inhibitor of insulin-like growth factor 1 receptor through structural modification of the parent natural molecule. J Med Chem. 2017;60:4949–4962.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee JE, Jeong SY, et al. 5,5ʹ-substituted indirubin-3ʹ-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010;53:3696–3706.
   PubMed Web of Science ®Google Scholar
• Jie C, Luo Z, Chen H, et al. Indirubin, a bisindole alkaloid from Isatis indigotica, reduces H1N1 susceptibility in stressed mice by regulating MAVS signaling. Oncotarget. 2017;8:105615–105629.
   PubMedGoogle Scholar
• Medina-Moreno S, Dowling TC, Zapata JC, et al. Targeting of CDK9 with indirubin 3ʹ-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PloS one. 2017;12:e0183425.
   PubMed Web of Science ®Google Scholar
• Clough BH, Zeitouni S, Krause U, et al. Rapid osteogenic enhancement of stem cells in human bone marrow using a glycogen-synthease-kinase-3-beta inhibitor improves osteogenic efficacy in vitro and in vivo. Stem Cells Transl Med. 2018;7(4):342–353.
   PubMed Web of Science ®Google Scholar
• Sato N, Meijer L, Skaltsounis L, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10:55–63.
   PubMed Web of Science ®Google Scholar
• Chen L, Huang C, Shentu J, et al. Indirubin derivative 7-bromoindirubin-3-oxime (7bio) attenuates abeta oligomer-induced cognitive impairments in mice. Front Mol Neurosci. 2017;10:393.
   PubMed Web of Science ®Google Scholar
• Toledo EM, Colombres M, Inestrosa NC. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol. 2008;86:281–296.
   PubMed Web of Science ®Google Scholar
• Sekhon S, Koo J. Indirubin: a novel topical agent in the treatment of psoriasis. Br J Dermatol. 2018;178:21.
   PubMed Web of Science ®Google Scholar
• Qi T, Li H, Li S. Indirubin improves antioxidant and anti-inflammatory functions in lipopolysaccharide-challenged mice. Oncotarget. 2017;8:36658–36663.
   PubMedGoogle Scholar
• Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, et al. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases. ACS Med Chem Lett. 2013;4:22–26.
   PubMed Web of Science ®Google Scholar
• Polychronopoulos P, Magiatis P, Skaltsounis AL, et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004;47:935–946.
   PubMed Web of Science ®Google Scholar
• Vougogiannopoulou K, Ferandin Y, Bettayeb K, et al. Soluble 3ʹ,6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase −3 alter circadian period. J Med Chem. 2008;51:6421–6431.
   PubMed Web of Science ®Google Scholar
• Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1:60–67.
   PubMed Web of Science ®Google Scholar
• Efstathiou A, Gaboriaud-Kolar N, Smirlis D, et al. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial glycogen synthase kinase-3 over leishmanial cdc2-related protein kinase 3. Parasit Vectors. 2014;7:234.
   PubMed Web of Science ®Google Scholar
• Efstathiou AG-KN, Myrianthopoulos V, Vougogiannopoulou K, et al. Indirubin analogues inhibit typanosoma brucei glycogen synthase kinase 3 short and T. brucei growth. submitted. 2018.
   Google Scholar
• Stuart K, Brun R, Croft S, et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest. 2008;118:1301–1310.
   PubMed Web of Science ®Google Scholar
• Heredia A, Natesan S, Le NM, et al. Indirubin 3ʹ-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV. AIDS Res Hum Retroviruses. 2014;30:403–406.
   PubMed Web of Science ®Google Scholar
• Cheng X, Merz KH. The role of indirubins in inflammation and associated tumorigenesis. Adv Exp Med Biol. 2016;929:269–290.
   PubMed Web of Science ®Google Scholar
• Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, et al. Natural-based indirubins display potent cytotoxicity toward wild-type and t315i-resistant leukemia cell lines. J Natur Prod. 2016;79:2464–2471.
   PubMed Web of Science ®Google Scholar
• Broecker-Preuss M, Becher-Boveleth N, Gall S, et al. Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3ʹ-oxime (7BIO). Cancer Cell Inter. 2015;15:97.
   PubMed Web of Science ®Google Scholar
• Liu L, Kritsanida M, Magiatis P, et al. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and akt signaling. Cancer Biol Ther. 2012;13:1255–1261.
   PubMed Web of Science ®Google Scholar
• Xingi E, Smirlis D, Myrianthopoulos V, et al. 6-br-5methylindirubin-3ʹoxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol. 2009;39:1289–1303.
   PubMed Web of Science ®Google Scholar
• Durieu E, Prina E, Leclercq O, et al. From drug screening to target deconvolution: a target-based drug discovery pipeline using leishmania casein kinase 1 isoform 2 to identify compounds with antileishmanial activity. Antimicrob Agents Chemother. 2016;60:2822–2833.
   PubMed Web of Science ®Google Scholar
• Grant KM, Dunion MH, Yardley V, et al. Inhibitors of leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother. 2004;48:3033–3042.
   PubMed Web of Science ®Google Scholar
• Brancaglion GA, Toyota AE, Cardoso Machado JV, et al. In vitro and in vivo trypanocidal activities of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-cromen-2-one, a new synthetic coumarin of low cytotoxicity against mammalian cells. Chem Biol Drug Des. 2018
   PubMed Web of Science ®Google Scholar
• MacLean LM, Thomas J, Lewis MD, et al. Development of trypanosoma cruzi in vitro assays to identify compounds suitable for progression in chagas’ disease drug discovery. PLoS Negl Trop Dis. 2018;12:e0006612.
   PubMed Web of Science ®Google Scholar
• Bastos TM, Barbosa MI, Da Silva MM, et al. Nitro/nitrosyl-ruthenium complexes are potent and selective anti-trypanosoma cruzi agents causing autophagy and necrotic parasite death. Antimicrob Agents Chemother. 2014;58:6044–6055.
   PubMed Web of Science ®Google Scholar
• Zong WX, Thompson CB. Necrotic death as a cell fate. Genes & Dev. 2006;20:1–15.
   PubMed Web of Science ®Google Scholar
• Juliany Cola Fernandes Rodrigues SHSaWdS. APOPTOSIS-LIKE DEATH IN PARASITIC PROTOZOA. Braz J morphol Sci. 2006;23:87–89.
   Google Scholar
• Tessarolo LD, de Menezes R, Mello CP, et al. Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to trypanosoma cruzi. Parasitology. 2018;145:1191–1198.
   PubMed Web of Science ®Google Scholar
• Maya JD, Cassels BK, Iturriaga-Vasquez P, et al. Mode of action of natural and synthetic drugs against trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem and Physiol Part A, Mol & Integr Physiol. 2007;146:601–620.
   PubMed Web of Science ®Google Scholar
• Manallack DT, Prankerd RJ, Yuriev E, et al. The significance of acid/base properties in drug discovery. Chem Soc Rev. 2013;42:485–496.
   PubMed Web of Science ®Google Scholar
• Sousa MC, Varandas R, Santos RC, et al. Antileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosine. PloS one. 2014;9:e89939.
   PubMed Web of Science ®Google Scholar
• Alirol E, Schrumpf D, Amici Heradi J, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: medecins sans frontieres experience in the democratic republic of the congo. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56:195–203.
   PubMed Web of Science ®Google Scholar
• Ferandin Y, Bettayeb K, Kritsanida M, et al. 3ʹ-substituted 7-halogenoindirubins, a new class of cell death inducing agents. J Med Chem. 2006;49:4638–4649.
   PubMed Web of Science ®Google Scholar
• Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem Biol. 2003;10:1255–1266.
   PubMed Web of Science ®Google Scholar
• Silva LHNV. Sobre uma cepa de Trypanosoma cruzi virulenta para o camundongo branco. Folia Clin Biol. 1953;20:191–207.
   Google Scholar
• Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with trypanosoma cruzi. Rev Inst Med Trop Sao Paulo. 1962;4:389–396.
   PubMedGoogle Scholar